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Abstract
In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained
increasing attention. Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing
to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles. The interplay
between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and
metabolites) or by the multifaceted functions of the surrounding extracellular matrix. Here, we dissect the most
recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which
include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-
related programs and metabolic reprogramming in tumor cells. Importantly, the recently unveiled heterogeneity in
CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression,
therapy resistance and relapse. However, despite the large amount of pre-clinical data, much effort is still needed to
translate CAF-directed anti-cancer strategies from the bench to the clinic.
Introduction
Solid tumors can be considered as aberrant organs,
which have undergone molecular and cellular reprogram-
ming, promoting a proliferative and invasive niche, ideal
for cancer cell propagation and homing at metastatic sites.
Like healthy organs, tumors are characterized by high
cellular heterogeneity, not only within the transformed
cell compartment (i.e. cancer stem cells, progenitor and
differentiated cancer cells). Indeed, tumors contain
peculiar cellular and non-cellular components, which
altogether form the tumor microenvironment (TME).
This complexity is a major hurdle in the understanding of
the mechanisms responsible for treatment failure. Cell
types within the TME include: neuro-endocrine, adipose,
endothelial, mesenchymal, immune-inflammatory cells as
well as fibroblasts [1]. Among stromal cells, fibroblasts are
particularly important because of their abundance (up to
80% of the tumor mass in pancreatic tumors [2]) and their
robust crosstalk with cancer cells. Fibroblasts, which are
usually quiescent, can be reversibly or irreversibly acti-
vated in response to different inputs occurring upon tissue
damages, generating the normal activated fibroblasts
(NAFs), also called myofibroblasts and characterized by
the expression of α-smooth muscle actin (α-SMA), a
marker of smooth muscle cells [3]. Recent data show that
during the acute inflammation process the reversible
activation of NAFs is mediated by the presence of growth
factors. In contrast, in chronic inflammation the acquisi-
tion of epigenetic alterations locks NAFs in a state of irre-
versible activation [4]. When fibroblasts’ activation persists
even in absence of the initial insults, they can promote
tumor initiation. It has been widely demonstrated that can-
cer cells interact with fibroblasts during all stages of disease
progression. Fibroblasts associated with cancer have been
named CAFs (reviewed in [4, 5]).
CAFs can derive from different cell types, such as
NAFs, epithelial cells following EMT, endothelial cells
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via endothelial-to-mesenchymal transition (EndMT),
bone marrow-derived cells (BMDCs), adipocytes and
stellate cells [6]. They are characterized by increased ex-
pression of markers such as α-SMA, fibroblast activation
protein (FAP), fibroblast specific protein 1 (FSP1 or
S100A4), VIMENTIN, and platelet-derived growth factor
receptor (PDGFR)-α and β [5]. Unfortunately, none of
these markers is specific to this cell subpopulation,
which is characterized by a high grade of heterogeneity,
thus making it more difficult to study CAFs’ role in
different pathological contexts.
Heterogeneity of Cancer-associated fibroblasts
Tumor heterogeneity, which is considered the driver of
current anti-tumor therapies’ failure, involves both the
transformed epithelial cells and the stromal cellular
components. This heterogeneity originates from intrinsic
(i.e. different cellular phenotype) and extrinsic factors
(i.e. tumor progression, treatments and spatial distribu-
tion). Consequently, tumor cells are exposed to different
signals in primary tumor versus metastatic environment,
in small versus large lesions, in the center versus the inva-
sive front. These findings have an important clinical value,
as cancer cells may be confined, in different steps of
tumor progression, in a favorable or hostile environment
that shapes their behavior and therapeutic response.
Therefore, elucidating the mechanisms underlying this
stromal heterogeneity may have a strong impact on the
prognosis of cancer patients and lay the foundations for
the development of new therapeutic protocols.
In this scenario, Ohlund and colleagues have reported
in pancreatic ductal adenocarcinoma (PDAC) the
existence of distinct subsets of CAFs with different
localization within the tumor. In particular, the authors
identify α-SMAhigh CAFs in direct contact with neoplas-
tic cells, while α-SMAlow CAFs localize distant from
cancer cells and display a strong paracrine release of
pro-inflammatory cytokines, including IL-6 [7].
A recent study by Costa and colleagues demonstrates
the existence of four CAF subsets (S1–4), with unique
properties and activation levels, which accumulate
differently in breast cancer subtypes (Luminal A, HER2
and Triple negative) [8]. In particular, by using six CAF
markers (CD29, FSP1, FAP, αSMA, PDGFRβ and
Caveolin1), the authors show that S1-CAFs are associated
with an immunosuppressive tumor microenvironment by
attracting T cells and promoting their differentiation into
T-reg, in contrast to S4-CAFs that are associated with
high CD8+ T cell infiltration. Further, Neuzillet and col-
leagues have confirmed by transcriptomic analysis in
PDAC the classification of CAFs into four subsets
(subtypes A-D) found in breast cancer [9]. As previously
demonstrated, each subtype possesses a specific pheno-
type and a prognostic impact. All four subsets express
ECM-related genes, while immune-related pathways are
selectively enriched in subtype C. Importantly, this classifi-
cation correlates with the one found in lung cancer by
Lambrecht et al., supporting the concept of fibroblasts’
intra-tumor heterogeneity with in vivo spatially distinct
CAF subsets within single tumors [10]. The authors have
identified specific markers to label three out of the four
CAF subsets, with Periostin as a marker of subtype A
(found at the invasive front of primary tumor and crucial
to the formation of tumor capsule and metastatic niche),
Myosin-11 for subtype B (enriched in larger tumors char-
acterized by lymph node metastases and poor prognosis),
and podoplanin in subtype C (immunogenic tumors).
In another study, Su et al. identify a specific subset of
CAFs, characterized by the expression of CD10 and
GPR77 and persistent NF-kB pathway activation, which
promotes tumor formation and chemoresistance in
breast and lung cancer [11]. In oral squamous cell
carcinoma (OSCC), Costea and colleagues put in evi-
dence the presence of two CAF subsets, with the CAF-N
population characterized by a phenotype and paracrine
activity more similar to normal fibroblasts, and the
CAF-D counterpart showing a different expression
pattern and high release of TGF-β [12]. Noteworthy, the
inhibition of CAF-N, intrinsically more motile, impairs
the invasion of adjacent OSCC cells, while neutralization
of CAF-D function by TGF-β blockade impairs keratino-
cytes’ EMT and invasive potential. This study postulates
the occurrence of two CAF subtypes both promoting
OSCC invasion by acting on different molecular mecha-
nisms of cancer cells.
Even in absence of a molecular or phenotypic
characterization, the existence of CAFs restraining
tumor growth has been first hypothesized in pancreatic
cancer. Two back-to-back reports have jointly demon-
strated that erasing α-SMA-expressing myofibroblasts in
two different genetically engineered mouse models
(GEMM) of PDAC resulted in a more aggressive tumor
and did not improve gemcitabine’s efficacy, owing to
suppressed immune surveillance and increased tumor
vascularization, respectively [13, 14]. More in detail,
Ozdemir and colleagues show that overall ablation of
α-SMA+ fibroblasts leads to more invasive and undiffer-
entiated tumors, more pronounced hypoxia, and
concomitant induction of EMT and cancer stem cells
(CSCs) enrichment. Importantly, the authors also notice
an enrichment in FoxP3+ T-reg cells upon CAFs
depletion and administration of an anti-CLTA4 antibody
significantly improved mice survival [13]. Similarly,
Rhim et al. demonstrate that Shh-deficient PDAC mice
harbor more aggressive and undifferentiated tumors with
a reduced number of α-SMA+ myofibroblasts and
increased vascularization [14]. Moreover, a recent work
by Patel et al. identifies in oral carcinoma two CAF
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subsets characterized by different levels of α-SMA
expression, the α-SMA- (C1) and α-SMA+ (C2) [15]. In
particular, C1 CAFs positively regulate proliferation and
concomitantly suppress self-renewal of oral cancer cells
by releasing BMP4, as compared to the C2 subset. In
line with these data, Brechbuhl et al. describe two CAF
populations that differentially express CD146 and play
conflicting roles in affecting efficacy of endocrine
therapy in luminal breast cancer [16].
Taken together, these findings suggest that a better
characterization of CAF subtypes and their specific role
in tumor progression could offer innovative therapeutic
tools for the development of anti-tumor treatments.
Notwithstanding, these results also entail the need for
caution in targeting CAFs in cancer patients, suggesting
that a combinatorial rather than a single-agent therapy
could be more effective.
Despite the very recent evidence regarding the pres-
ence of CAFs endowed with anti-tumorigenic potential,
CAFs are well known for their role in the establishment
of favorable conditions for in situ tumor growth and
metastatic spread of cancer cells [17]. Among the
plethora of mechanisms regulated by CAFs in tumor
progression, the modulation of cancer stemness, EMT
and therapy resistance has direct repercussions on onco-
logic patients’ survival. In this scenario, we will review
here the most recent findings regarding CAFs-mediated
metastatic behavior and resistance to therapy.
Mechanisms of CAF-mediated control of tumor
progression
Within the tumor bulk, the more undifferentiated cancer
cells can fluctuate between different states due to their
plasticity, which has been reported as a peculiarity of
CSCs, together with tumorigenic potential and
self-renewal [18]. Initially, CSCs were isolated and char-
acterized in acute leukemia [19, 20] and then they were
identified in many other cancers [21]. The interest of the
scientific community in this cellular population origi-
nates from growing evidence that supports its involve-
ment in crucial steps of tumor progression, including
tumor initiation and growth, metastases formation, drug
resistance and relapse, being responsible for minimal
residual disease (MRD). Cancer stemness and mesenchy-
mal phenotype have recently been demonstrated to
strongly correlate. Indeed, it has been observed that can-
cer cells that acquire EMT traits gain CSC-like proper-
ties, and CSCs often undergo EMT in order to generate
metastases [22–24]. In fact, the EMT process can be
crucial during the dissemination step that precedes
metastatic colonization [25]. However, the transition be-
tween an epithelial- to a mesenchymal-like phenotype is
not a sharp switch, but rather occurs through different
steps, thus defining a gradient of metastable phenotypes,
where specific mesenchymal and epithelial features
coexist and eventually lead to the acquisition of a stable
EMT programme [26]. During the first stage, character-
ized by a continuous source of stimuli driving the
acquisition of the mesenchymal state, we observe the ac-
tivation of specific pathways driving the EMT, which can
be reverted once the TME stimuli cease. Differently,
gaining a stable EMT phenotype includes a gene expres-
sion reprogramming, which involves the activity of
specific transcription factors, non-coding RNAs or
epigenetic changes, and it often occurs as a result of
prolonged exposure to stimuli driving EMT [27]. It is
clear that CAFs can regulate EMT in cancer cells, how-
ever the underlying mechanisms are not completely
understood. Here, we summarize the most recent find-
ings regarding the crosstalk that defines the cooperation
between CAFs and cancer cells in different phases of
tumor progression. Such interplay can occur through dif-
ferent mechanisms, including CAFs’ altered secretome,
which consists of growth factors and cytokines directly in-
volved in the positive regulation of cancer cell survival,
proliferation, stemness, and resistance to therapy. More-
over, by releasing cytokines and matrix metalloproteinases
(MMPs), CAFs enhance tumor angiogenesis, local inflam-
mation and extra-cellular matrix (ECM) stiffness.
CAFs paracrine effects
One of the most studied CAFs-released cytokines is the
transforming growth factor-β (TGFβ), whose pathway is
crucial in driving tumor progression in different cancer
models [28]. TGFβ binds a complex of transmembrane
receptor serine/threonine kinases (types I and II) and
induces trans-phosphorylation of the type I receptor by
the type II receptor kinases. Activated type I receptors
phosphorylate Smad2/3 and these receptor-activated
Smads (R-Smads) form a complex with the
common-mediator Smad (co-Smad) Smad4. Activated
Smad complexes translocate into the nucleus, where
they regulate transcription of target genes by cooperating
with DNA-binding transcription factors and coactivators
(canonical signaling) [29]. In addition, TGFβ is also able to
regulate other cancer-related pathways, including MAPK
and PI3K/Akt, through the non-canonical signaling [30].
TGFβ-driven effects have been demonstrated to be highly
cell-type dependent [31]. Although it exerts a dual role
during different phases of tumor progression, TGFβ path-
way gained a great consideration in oncology since it has
been found deregulated in many cancers [32]. In healthy
tissues and in early stages of tumor formation, TGFβ
activation plays a protective role inducing cell-cycle arrest
and apoptosis [33], whereas in advanced cancer it regu-
lates the acquisition of a mesenchymal phenotype, hence
being a driver of the metastatic disease [34]. In addition to
its involvement in the regulation of EMT [35, 36], it has
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been reported a direct link between activation of TGFβ
and cancer stemness [37, 38]. Zhuang et al. have recently
shown that TGFβ1 is highly present in CAF-conditioned
medium (CAF-CM) and induces EMT in bladder cancer
cells by activating the canonical TGFβ signaling through
the activation of Smad2 [39]. In this model, TGFβ is suffi-
cient to induce over-expression of EMT-related genes, in-
cluding VIMENTIN, FIBRONECTIN, SNAI1, ZEB1 and
ZEB2. The authors have demonstrated that this cancer cell
reprogramming is driven by the up-regulation of a long
non-coding RNA (lncRNA), ZEB2NAT, a natural anti-
sense transcript of ZEB2. In line with these findings, TGFβ
pathway has been shown to control the epigenetic signa-
ture of cancer cells by up-regulating the lncRNA HOX
transcript antisense RNA (HOTAIR) in breast cancer [40].
HOTAIR mediates H3K27 tri-methylation with conse-
quent silencing of tumor suppressors in many cancer
types [41], including breast cancer, where it is reported to
promote drug resistance and cancer stemness [42]. Here,
Ren and colleagues demonstrate that the TGFβ1/HOTAIR
axis, by targeting CDK5 signaling, promotes the meta-
static capacity of breast cancer cells, thus suggesting that
its targeting may be considered a novel strategy for the
treatment of breast cancer. The pronounced secretion of
TGFβ1 by CAFs in breast cancer promotes an aggressive
phenotype in tumor cells also through direct activation of
EMT, with decreased expression of E-CADHERIN and
over-expression of VIMENTIN, Fibronectin1 (FN1),
MMP2 and MMP9 [43]. Enhanced TGFβ signaling has
been identified in CAFs from colorectal cancer subtypes
with poor prognosis, as part of a stromal signature that
correlates with disease relapse. TGFβ-activated fibroblasts
actually promote tumor initiation in functional assays and
administration of a TGFβR1-specific inhibitor in a
metastatic mouse model of colorectal cancer impairs the
capacity of tumor cells to thrive in the liver over the
colonization phase [44].
Other important signaling pathways that drive the
gaining of mesenchymal traits are MAPK, PI3K/Akt,
Wnt/β-catenin and JAK/STAT [45]. These pathways are
regulated by growth factors and inflammation mediators
commonly released by CAFs, including hepatocyte
growth factor (HGF) [46], stromal-derived factor-1α
(SDF1) [47], osteopontin (OPN) [48], fibroblast growth
factor (FGF) [49], interleukin-6 (IL-6) [50]. We have
identified HGF, SDF1 and OPN as the key cytokines re-
leased by CAFs able to reprogram colorectal cancer cells
toward CSCs endowed with metastatic potential. Briefly,
such CAF-derived signals induce expression of the func-
tional CSC marker CD44v6 through activation of the
Wnt/β-catenin signaling pathway, which fosters migra-
tion and metastasis [24]. Lineage tracing of colorectal
CSCs in mouse xenografts performed by Lenos KJ et al.
has further highlighted the role of CAFs in conveying
stem cell functionality (meant as clonogenic capacity) to
neighboring cells at the invasive edge of the tumor.
Notably, the most abundant secreted factor expressed in
murine CAFs was OPN, and xenografts derived from
OPN-overexpressing CSCs displayed a homogeneous
distribution of clonogenic cells throughout the tumor
bulk, with no significant difference between centre and
edge. An important implication of this study is that non
clonogenic cancer cells can acquire self-renewal ability
as soon as they gain access to the right niche, enriched
in CAF-secreted OPN [48].
CAF-derived HGF promotes cancer cell tumorigenic
and metastatic potential by activating the HGF/c-MET
pathway [51]. In this work, Ding and colleagues unveil
the effects of CAFs-released HGF in the promotion of
proliferation, migration and invasion in MET-unampli-
fied gastric cancer cells. HGF ligand, by binding the
c-MET receptor, drives a plethora of intracellular signal-
ing pathways that regulate several aspects of tumor cells,
including survival, stemness, EMT, dissemination and
clonogenic potential [52]. The versatile biological effect
of HGF in cancer cells is given by its interaction and co-
operation with other crucial pathways (MAPK, PI3K/
Akt, JAK/STAT) that are considered as drivers of tumor
initiation and progression. In fact, by regulating the ex-
pression of IL-6R, HGF also activates the IL-6/IL-6R/
JAK2/STAT3 pathway that in turn augments the expres-
sion of c-MET with a positive feedback regulation [51].
The coordination of these two pathways drives tumori-
genic progression of cancer cells in response to CAFs’
paracrine activity. IL-6 is an inflammatory cytokine that
binds its membrane receptor IL-6Rβ (gp130) that, upon
dimerization with IL-6Rα, activates the intracellular
JAK/STAT pathway. As for other cytokines, IL-6
driven-effects are also extended to other pathways, thus
regulating several biological responses in target cells, in-
cluding the activation of MAPK, PI3K, and Notch, which
play an important role in inflammatory disease and
cancer development [53]. In addition, IL-6 serves as a
platform to recruit immune cells to tumors and enhance
the production of pro-inflammatory cytokines, promot-
ing a chronic inflammatory environment.
Further, the regulation of PI3K/Akt in cancer cells by
CAFs has recently been investigated by Yu et al., who
demonstrate that the secretion of periostin (POSTN), by
binding the Protein tyrosine kinase 7 (PTK7), increases
cell proliferation and invasion of head and neck cancer
cells [54]. PI3K activation arises from the binding of
growth factors or cytokines to the cell surface receptor
tyrosine kinase (RTK). This leads to the intracellular
activation of the catalytic subunit p100 that in turn forms
heterodimers with the regulatory subunit p85, triggering
the formation of phosphatidylinositol-3,4,5-trisphosphate,
PI(3,4,5) P3 (PIP3), a second messenger that activates
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several downstream signaling molecules, including AKT.
Once activated, AKT can phosphorylate and activate its
downstream effectors including GSK3, FOXO or mTOR
regulators. This pathway controls several aspects of cancer
cells behavior, including proliferation, metabolism, EMT
and survival [55].
All these clinical and preclinical studies demonstrate
the need to target the interaction between cancer cell
surface receptors and stromal-secreted factors in order
to ameliorate the outcome of cancer patients.
Cancer cells-mediated CAFs reprogramming
The crosstalk between CAFs and cancer cells, in particu-
lar CSCs, has been described as bi-directional. CSCs not
only drive the transition of normal fibroblasts (NFs) into
CAFs, but they also hijack fibroblast activity for their
own benefit. Beside its key role in driving the EMT in
cancer cells, TGFβ has been shown to reprogram also
CAFs. Calon and colleagues have demonstrated for the
first time that TGFβ released by colon cancer cells
activates STAT3 pathway in stromal cells, which in turn
enhance their secretion of IL-11 that increase the meta-
static potential of cancer cells [56]. In a recent work,
Valenti et al. demonstrate that CSCs, which are prefer-
entially located at the tumor-stroma edge, secrete Sonic
Hedgehog (SHH) that in turn stimulates the Hedgehog
signaling in adjacent CAFs, thus leading to a boost in
their proliferative potential, growth factors release
(IGF-1, ACTIVIN A, NOV and LIF) and ECM depos-
ition [57]. Although the presence of CAFs and their
interplay with cancer cells has been observed in both
primary tumor growth and distant metastases, their role
in different steps of tumor progression is still object of
investigation. Accomplishment of the metastatic
colonization process requires the EMT phenotype to be
switched off once cancer cells are seeded in distant sites,
in order to give rise to macrometastases. Metastasis ini-
tiating cells (MICs), which originate from the primary
tumor, are characterized by a partial and reversible
mesenchymal-like phenotype and have been reported to
strongly activate metastasis-resident fibroblasts [58].
Del-Pozo-Martin and colleagues have recently demon-
strated that in the first phase of metastatic niche induc-
tion in breast cancer, AXL+ MICs activate fibroblasts by
thrombospondin 2 (THBS2) release. This is followed by
enhanced BMP signaling activation and TGFβ
down-regulation that promote the acquisition of an
epithelial-like phenotype, necessary for the metastatic es-
tablishment in the second phase of the process [58]. A
further demonstration of the importance of the mutual
interplay between cancer cells and CAFs has been pro-
vided by Giannoni et al., who have demonstrated that
MMPs released by CAFs induce the expression of IL-6
in mesenchymal prostate cancer cells, which in turn
activates CAFs [59] (Fig. 1a).
CAFs role in ECM remodeling
The extracellular matrix is a complex network of macro-
molecules such as collagens, elastin, fibrin and proteogli-
cans. ECM confers support to the tissues and aids in
maintaining their architecture and integrity, contributing
to their functional roles with a tight regulation of cell
growth, migration, protein synthesis and secretion [60].
ECM structure undergoes constant remodeling, main-
taining the balance between synthesis and degradation.
ECM functions as a barrier, anchorage site, movement
track, but it can also initiate or regulate signaling events
by interacting with various cell surface molecules includ-
ing integrins, syndecans and discoidin domain proteins
[61]. Integrins and their associated RTK are involved in
cellular response to biochemical and physical changes.
In ECM there are also non-structural proteins, which
act as precursors of signaling molecules and proteins
called matricellular proteins [62] capable of modulating
biological processes in a context-dependent fashion,
including thrombospondin1–2 (TSP), secreted protein
acidic and rich in cysteine (SPARC), tenascin C, and
osteopontin [63].
ECM is a dynamic system that under pathological
conditions alters its physical and biochemical properties,
such as its elasticity and molecular composition [64].
Altered ECM is a common condition in cancer and it
has been shown to be required for cancer progression
[65]. Stromal cells in proximity of the ECM, including
CAFs, immune cells and mesenchymal stem cells,
orchestrate a sophisticated program based on cell-ECM
interactions in both physiological and pathological con-
ditions [47, 66]. These cells contribute to ECM remodel-
ing by secreting important proteases such as MMPs
[67]. In physiological conditions, the main role of fibro-
blasts is to produce components of ECM as fibronectin,
type I, III, V collagens, which are indispensable compo-
nents of connective tissue, maintaining ECM homeostasis
and turnover. Besides the demonstrated up-regulation of
type I, III, V collagens, proteoglycans and glycosaminogly-
cans, the transition of NFs to CAFs promotes the deposit
of collagens IV, VII, XI, and XV [68]. The increased
deposition of collagens contributes to the ECM stiffening.
This process matches with higher activity of LOX-like
proteins that are responsible of establishing both intra-
and inter-molecular covalent crosslinking of collagen, by
oxidative deamination of specific lysine and hydroxylysine
residues [65, 69]. The remodeling of the extracellular
matrix, represents one of the most important features of
cancer progression. Indeed, numerous MMPs are shown
to be over-expressed in different types of tumors. MMP3
over-expression in CAFs was observed in mammary
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Fig. 1 (See legend on next page.)
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glands [70], MMP2 is over-expressed in gliomas [71],
whereas MMP1 was observed to increase in melanoma
[72] and breast cancer [73]. Moreover, CAFs are actively
involved in the secretion of proteases, like uPA, which can
cleave and activate MMPs [74].
By cell-cell contact, CAFs are also reported to exert a
physical momentum that regulates cancer cell invasion,
as highlighted by the observed collective invasion and
migration of CAFs and cancer cells [75]. Carcinomas
can retain an epithelial phenotype during tumor
progression that limits the degradation and invasion of
the ECM [76, 77]. In this context, the possibility to de-
velop a cooperative invasive strategy could be decisive
for the success of the metastatic process. This partner-
ship in crime of CAFs and cancer cells for the formation
of distant metastatic foci takes place through different
strategies. CAFs can remodel the ECM thus creating the
path for cancer cells to migrate [78]. Moreover, cancer
cells can simply follow CAFs during migration through
the ECM, being in steady communication due to the se-
cretion of chemokines that generate a chemotactic
gradient. This process has recently been investigated by
Neri et al., who demonstrated that mesenchymal-like
cancer cells increase the matrix-remodeling ability of
CAFs, thus leading to the joint invasion of both CAFs
and cancer cells [79].
Although physical ECM remodeling is crucial to allow
cancer cells’ migration, it has been proposed a different
and more complex mechanism in which ECM remodel-
ing is force-mediated. For instance, the numerous
attachment-points allow CAFs to transmit a mechanical
force to ECM, driven by Myo II-contractility [80]. A
recent study by Erdogan and collaborators shows that
Fibronectin, which is highly expressed by CAFs,
promotes migration of cancer cells [81]. Briefly, CAFs
are implicated in ECM remodeling by promoting the
alignment of high amounts of Fibronectin in parallel fi-
bers, which guide the cancer cells in their directional
migration. In particular, the over-expression of Myosin
II and PDGFRα by CAFs, through the α5β1 integrin,
leads to an augmented contractility and traction force.
In this process, α5β1 acts as a mechanotransducer, while
PDGFRα enhances its activity (Fig. 1b).
Mechanisms of CAF-mediated therapy resistance
As already discussed, the complexity of cancer does not
rely merely on intrinsic features of tumor cells. Rather,
the interconnections between transformed cells and dif-
ferent components of the tumor microenvironment
exert a pivotal role in cancer onset, homeostasis, spread
and response to insults such as nutrient/oxygen
deprivation or therapeutic drugs. Recent studies have
reported an increase of the stromal compartment in
colorectal and breast cancer of chemo-treated patients
[11, 82]. This phenomenon has been recapitulated in
mouse models where resistant tumor xenografts display
a larger stromal compartment [83]. These observations
imply a putative role of the TME in promoting the
adaptive response to therapeutic pressure. Indeed,
chemotherapy-induced activation of the stromal
compartment supports the survival of residual cancer
cells by fostering pro-survival pathways, stemness traits
and/or metabolic reprogramming and partially accounts
for tumor resistance and recurrence [84]. Specifically,
sustained NF-kB activation in CAFs exerts a crucial role
in orchestrating the molecular mechanisms underlying
their tumor-supportive function upon therapeutic
insults, through the release of paracrine signals such as
cytokines, exosomes and metabolites [11, 84–86]. Unrav-
eling the crosstalk of cancer cells with TME is therefore
compulsive in order to identify novel therapeutic
approaches and to overcome resistance to the existing
regimens. Notably, non-transformed components of the
tumor are genomically more stable than transformed
cells, entailing a more durable response to drugs and
candidating tumor stroma as an appealing therapeutic
target.
Secretion of cytokines
Under therapeutic pressure, cytokines released by CAFs
mediate the activation of different signaling cascades in
tumor cells leading to resistance and eventually relapse.
(See figure on previous page.)
Fig. 1 Schematic diagram showing the effects of CAFs on cancer cell metastatic behavior. a) Activated fibroblasts (NAF) originate from normal
fibroblasts (NF) upon exposure to inflammatory cytokines. Following contact with cancer cells, they can originate the cancer-associated fibroblasts
(CAFs) with enhanced proliferative and paracrine potential. The paracrine activity of CAFs and cancer cells underlying the bidirectional crosstalk
between the two cell populations with the specific involved deregulated pathways are depicted. The arrows indicate the stimulatory effect of
each cytokine. The induction of EMT in cancer cells relies on the activation of transcription factors, lncRNAs and epigenetic changes. b) CAFs-
mediated effect on mesenchymal-independent (cancer cells maintain an epithelial-like phenotype) invasive potential. Different strategies are
adopted by CAFs to facilitate cancer cells invasion of ECM, thus favoring their metastatic potential. Among these, we find the co-migration, by
which CAFs and cancer cells migrate together thanks to the expression of cell membrane junctions; the ECM digestion that consists in the
production of proteases by CAFs that is accompanied by the release of chemokines acting as chemoattractants for cancer cells; the force-
mediated ECM remodeling that consists in the augmented contractility of the ECM and the concomitant alignment of Fibronectin (Fn), thus
offering to the cancer cells a preferential route in the invasive process
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In prostate cancer, DNA damage induced in CAFs
upon exposure to chemotherapy triggers transcriptional
activation of WNT16B via NF-kB [85]. WNT16B acts as
a paracrine signal that activates the canonical Wnt
program in tumor cells, which mitigates the effects of
cytotoxic chemotherapy in vivo in favor of disease pro-
gression. In pancreatic ductal adenocarcinoma, constitu-
tive NF-kB activity in both CAFs and tumor cells is
sustained by a positive mutual loop involving secreted
IL-1β and the cognate receptor IL-1 receptor–associated
kinase 4 (IRAK4), expressed on both cell types. Interest-
ingly, CAF-conditioned medium is able to rescue PDAC
cells from gemcitabine-induced apoptosis in vitro, and
this protective effect is abrogated upon IRAK4 knock-
down in CAFs. In PDAC mouse models, administration
of either IL-1β-neutralizing antibodies or an IRAK4 in-
hibitor potentiates the effect of gemcitabine in suppress-
ing tumor growth and fibrosis [86]. Further, IL-6
secreted by CAFs was reported to drive chemotherapy
resistance in esophageal squamous cell carcinoma
(ESCC). Briefly, IL-6 increases the expression of CXCR7
in ESCC cells via STAT3/NF-κB signaling, ultimately
fostering their chemoresistant phenotype of ESCC cells
upon treatment with cisplatin both in vitro and in sub-
cutaneous xenografts. Consistently, CXCR7 expression is
significantly higher in ESCC tissues from patients that
had developed chemoresistance compared to chemosen-
sitive ones [87]. Cisplatin treatment has also been shown
to trigger AKT and ERK1/2 signaling pathways in ESCC
cells in response to the release of Plasminogen activator
inhibitor-1 (PAI-1) by CAFs. Activation of such
pro-survival pathways exerts a protective effect against
DNA damage, reactive oxygen species (ROS) accumula-
tion and apoptosis. Both in vitro and in vivo analyses
prove the efficacy of PAI-1 blockade, as shown by the
synergistic effect of its inhibitor, Tiplaxtinin, combined
with cisplatin. Finally, immunohistochemical staining of
PAI-1 in samples from ESCC patients who receive
cisplatin after surgery demonstrates a correlation
between high PAI-1 expression in CAFs and a worse
progression-free survival after chemotherapy [88].
Besides boosting pro-survival pathways in tumor cells,
another important route to chemoresistance consists in
supporting the CSC subpopulation, which is intrinsically
resistant to cytotoxic drugs owing to its slow-cycling or
quiescent state. One of the hallmarks of CSCs is indeed
the ability to endure multiple insults, leading to therapy
resistance [89, 90]. This “robustness” is partly due to
cell-intrinsic mechanisms, but stromal cues are also
crucial in inducing or maintaining stemness features as a
mechanism of acquired resistance. Although colorectal
cancer stem cells (CR-CSCs) display cell-autonomous
resistance to chemotherapy, conditioned medium from
chemo-treated human CAFs further enhances this
phenotype through IL-17A -dependent activation of the
NF-kB pathway and its downstream target ERK1/2 [82].
A different CAF-secreted mediator supporting chemo-
therapy resistance in CR-CSCs is TGFβ2, which induces
non canonical SHH pathway in CSCs, thus sustaining
stemness features through GLI2-driven transcription.
HIF1α has been shown to cooperate with CAF paracrine
signals to activate GLI2, which then promotes the resist-
ance to 5-fluorouracil + oxaliplatin (FOX) therapeutic
regimen. Furthermore, in patients’ data sets, sustained
expression of TGFβ2/GLI2/HIF1α correlates with re-
lapse after chemotherapy, further highlighting the thera-
peutic potential of TGFβ2 and GLI2 targeting [91]. In
breast and lung cancer, a survival niche for CSCs is pro-
vided through IL-6 and IL-8 secretion by CD10+/GPR77
+ fibroblasts, a functionally distinct subset enriched in
biopsies of chemoresistant tumors prior to chemother-
apy [11]. Furthermore, in breast cancer and PDAC, CAF
secretion of ELR motif–positive (ELR+) chemokines
following neoadjuvant chemotherapy has been shown to
push CXCL2+ cancer cells toward a stem cell status with
high invasive features [84].
As already pointed out, in the complex crosstalk be-
tween different cell types within a tumor, also the behav-
ior of stromal cells can be shaped by the interaction
with cancer cells. Release of the Hedgehog ligand by
cancer cells can stimulate CAFs to produce a supportive
niche via the secretion of FGF5 in triple negative breast
cancer (TNBC). In TNBC mouse models, the use of
Smoothened (Smo) inhibitors is able to revert this cas-
cade of signals, reducing stemness features of tumor
cells and increasing sensitivity to docetaxel, thus limiting
the metastatic burden [92]. The mutual reprogramming
of cancer and stromal cells is generated by an intricate
circuitry of paracrine and autocrine signals that are the
main determinants (together with genetic aberrations) of
cancer onset, progression and clinical behavior. In breast
cancer, the crosstalk with CAFs through PDGF-CC is a
main determinant of the molecular subtype and blocking
PDGF-CC is sufficient to revert basal-like resistant tu-
mors into an ERα-positive subtype that responds to
endocrine therapies [93]. Specifically, basal-like cancer
cells express sustained levels of PDGF-CC, which stimu-
lates CAFs to secrete stanniocalcin1 (STC1), HGF and
insulin growth factor binding protein 3 (IGFBP3). In a
feedback loop, the concerted action of these factors is
able to suppress luminal-like features in cancer cells and
sustain resistance to tamoxifen.
TME-driven drug resistance is not restricted to
conventional DNA-damaging chemotherapy, but rather
concerns compounds that rely on different mechanisms
of action, included oncogene-targeted drugs. The
mechanisms underlying acquired resistance to targeted
therapies have so far been explored through genomic
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profiling of tumor cells, which led to the identification
of genetic alterations either in the target itself
(“on-target” resistance) or in other downstream or paral-
lel pathways (“off-target” resistance) that eventually
compensated for the drug-inhibited oncogene. Hence,
the contribution of the tumor-stroma interplay to
non-cell-autonomous mechanisms of resistance to tar-
geted agents has been underestimated. Recent evidence
has shed light on the role of CAF-derived paracrine
signals in conveying resistance to epidermal growth fac-
tor receptor (EGFR) targeted therapy. A co-culture
screening has been employed to show that several stro-
mal cell types secrete signals responsible for resistance
to drugs, particularly to oncogene-targeted therapeutics
[94]. HGF has been described as the main mediator of
stroma-induced resistance to BRAF inhibitors in BRAF
mutated melanoma, colorectal cancer (CRC) and glio-
blastoma, by activating MAPK and PI3K/Akt signaling
in tumor cells via MET receptor [70]. Interestingly, a
parallel MET signaling cascade triggered by
CAFs-derived HGF was unveiled in KRASwt colorectal
CSCs developing resistance to EGFR inhibition [95].
Although KRASwt CSCs isolated from xenografts are
intrinsically sensitive to EGFR targeting, exposure to
CAF-conditioned medium impairs the pro-apoptotic
effect of cetuximab and gefitinib. Further, concomitant
administration of cetuximab and MET inhibitor
(JNJ-38877605) results in a more pronounced tumor re-
gression compared to cetuximab monotherapy in vivo.
Noteworthy, HGF expression in a public dataset of hu-
man KRASwt metastatic CRCs who progressed on cetux-
imab is significantly higher compared to responders.
Overall, these findings identify a non-cell-autonomous
mechanism of acquired resistance that contributes to re-
lapse of KRASwt metastatic CRC patients under EGFR
targeted therapy, thereby underscoring the inadequacy
of the mutational status in predicting therapeutic
outcome. In cholangiocarcinoma (CCA), a different
mechanism of CAFs-induced resistance to EGFR tyro-
sine kinase inhibitors (TKIs) has been described. Briefly,
CCA cells chronically treated with erlotinib exhibit an
up-regulation of insulin receptor (IR)/insulin-like growth
factor 1 receptor (IGF1R) signaling. Mechanistically, a
positive feedback circuitry involving IR/IGF1R signaling
and CAF-secreted IGF2 fuels both erlotinib resistance in
CCA cells and activation of hepatic myofibroblasts. Ac-
cordingly, combined treatment with erlotinib and an IR/
IGF1R inhibitor impairs growth of resistant tumor xeno-
grafts and reduces their stromal content [96] (Fig. 2a).
Delivery of exosomal vesicles
Besides the secretion of soluble factors, the release of
exosomal vesicles is crucial to vehicle paracrine signals
that drive cancer cell aggressiveness and therapy
resistance. Exosomes are membrane vesicles of 30–100
nm in diameter that contain proteins, DNA, mRNAs
and miRNAs. Secreted exosomes are uptaken by
neighboring cells via endocytosis and vesicle content is
released into the cytoplasm of recipient cells.
Exosome-delivered RNAs have been described as pivotal
mediators of tumor progression and resistance and
powerful biomarkers [97–99]. More recently, the role of
exosome transfer in TME-orchestrated resistance has
been highlighted. In PDAC, treatment with gemcitabine
stimulates in resistant CAFs the secretion of exosomes
that deliver SNAIL mRNA and its transcriptional target
miR-146, thus conferring resistance to recipient cancer
cells [100]. In ovarian cancer, miR-21 transfer from
CAFs and Cancer Associated Adipocytes (CAAs) to can-
cer cells, stimulates cell motility and inhibits apoptosis
thus enhancing chemoresistance, through its direct tar-
get apoptotic protease activating factor-1 (APAF1) [101].
Further, a mouse model of hormonal therapy resistance
in luminal breast cancer has been exploited to elucidate
the role of CAF-derived exosomes. Autocrine IL-6/
STAT3 signaling fuels CAFs proliferation and stimulates
the horizontal transfer of miR-221/222high microvescicles
to cancer cells. The uptake of miR-221/222 determines
the induction of Notch-mediated CD133high phenotype,
which is responsible for resistance. IL-6 targeting abro-
gates this circuitry, hence blocking resistance to hormone
therapy (HT). This mechanism is recapitulated also in
CAFs derived from patients’ bone metastases [102].
Interestingly, in breast cancer the release of exosomes by
stromal components determines the transfer of many
non-coding RNAs (ncRNAs) and transposable elements
to cancer cells, which activate STAT1-mediated anti-
viral response. Moreover, juxtacrine signaling of
neighboring stromal cells induces the activation of the
NOTCH3 pathway that converges into the STAT1
activation. These responses are able to select cancer
cell subpopulations, enriching for tumor-initiating
cells resistant to therapies [103].
In conclusion, exosomal transfer, together with other
paracrine and juxtacrine signals, constitutes a major
communication channel exploited by CAFs and other
stromal components to sustain tumor progression and
chemoresistance.
Metabolic reprogramming of tumor cells
Tumor cells mainly rely on glutamine and glucose as
energy sources and hijack CAF metabolism in order to
meet their metabolic needs. Metabolic coupling between
tumor cells and CAFs has been described as a mechan-
ism of mutual adaptation to low nutrients availability
that could be harnessed for novel therapeutic ap-
proaches [104–106]. Here, we will focus on the implica-
tions of such complementary metabolic reprogramming
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for the outcome of existing therapeutic strategies. Multi-
drug resistance can be triggered in cancer cells by the
exchange of metabolites with surrounding CAFs that act
as signal molecules inducing specific programs as differ-
entiation or metabolic switches. For instance in prostate
cancer, increased glutamine synthesis following macropi-
nocytosis of extracellular fluid has been detected in
primary CAFs and correlates with constitutive activation
of Ras signaling [107]. In turn, CAF-secreted glutamine
fuels prostate cancer mitochondrial metabolism and
induces neuroendocrine differentiation, orchestrating an
adaptive response to androgen signaling deprivation
therapy (ADT). Consistently, greater blood glutamine
levels have been detected in prostate cancer patients
who progressed on ADT compared to responders.
Notably, counteracting the uptake of stromal glutamine
restores sensitivity to ADT in a castration-resistant
xenograft model.
As a mechanism of adaptation to a glucose-deprived
microenvironment, a metabolic switch towards aerobic
glycolysis, known as Warburg effect, occurs in cancer
cells. Interestingly, it has been reported that cancer cells
can induce aerobic glycolysis in stromal cells, activat-
ing a loop that results in multidrug resistance [108].
Specifically, breast cancer cells with active PI3K/Akt
signaling induce the Warburg effect in adjacent CAFs,
via cytoplasmic translocation of the nuclear
G-protein-coupled estrogen receptor (GPER) and the
aberrant activation of a GPER/cAMP/PKA/CREB sig-
naling axis. The extra pyruvate and lactate provided
by glycolytic CAFs boost cancer cell metabolism and
confer multidrug resistance. Accordingly, both chemo-
therapy- and tamoxifen-resistant tumor samples show
a strong GPER cytoplasmic expression associated with
an elevated metabolic activity in both local and
metastatic sites, as measured by positron emission
tomography/computed tomography (PET/CT). How-
ever, how cancer cells can instruct CAFs to trigger
resistance-mediating pathways is poorly understood.
The study from Apicella and colleagues shed light on
a metabolism-based mechanism of adaptive resistance
to MET and EGFR TKIs [83]. An in vivo model of
adaptive resistance to MET TKIs was generated by
long term administration of the maximum tolerated
dose of a MET inhibitor in mice bearing a subcutane-
ous tumor xenograft of a non-small cell lung cancer
(NSCLC) cell line, until resistance onset. Interestingly,
tumor cells isolated from resistant xenografts are not
intrinsically resistant in vitro but maintain the ability
to reproduce resistant tumors upon re-injection,
hinting at the involvement of cancer-derived signals
activating the surrounding stroma. Indeed, resistant
cells display a metabolic reprogramming towards aer-
obic glycolysis resulting in the production of high
amounts of lactate. Lactate functions as the signaling
molecule instructing CAFs to secrete HGF, the
soluble cue responsible for the induction of MET TKI
resistance in tumor cells, as previously reported [109].
Consistently, either pharmacologic or genetic targeting
of lactate metabolism in tumor cells isolated from
resistant xenografts completely prevents the onset of
resistance to MET inhibition upon subcutaneous
re-injection. Importantly, the role of the lactate-HGF
axis in mediating adaptive resistance has been recapitu-
lated for the EGFR TKI erlotinib, suggesting that the pre-
vious results can be applied to other oncogene-addicted
lung cancer subtypes. Accordingly, an increased produc-
tion of tumor lactate and stromal HGF were detected in
advanced NSCLC patients upon the emergence of
resistance to EGFR TKIs currently used in clinical practice
(erlotinib and gefitinib), thus corroborating the clinical
relevance of the reported findings.
Collectively, compelling experimental evidence has
indicated coupled metabolic reprogramming of tumor
cells and associated CAFs as a mechanism of mutual
adaptation to therapeutic pressure, thus underscoring
the need for targeting strategies aimed at sensitizing to
conventional therapies (Fig. 2b).
Targeting CAFs to hit cancer progression
CAFs are major players in driving onset and progression
of solid tumors by affecting cancer cells’ plasticity, inva-
sion and colonization ability, and therapeutic response.
Their diverse tumor-supportive roles, combined with
genetic stability and relative abundance among stromal
cells, make these tumor cells’ henchmen an appealing
therapeutic target. Here, we will briefly highlight the
major advances and challenges in the development of
(See figure on previous page.)
Fig. 2 CAFs promote resistance to anti-cancer therapies through paracrine signals and mutual metabolic reprogramming. Upon exposure to a
therapeutic insult, CAFs support an adaptive response in cancer cells that ultimately leads to therapy failure. a) Drug treatment triggers NF-kB and
JAK/STAT signaling in CAFs. CAFs-released paracrine signals include exosome-mediated delivery of mRNAs and ncRNAs and a broad range of
cytokines (mainly interleukins and growth factors). Activated pathways in cancer cells include pro-survival, anti-apoptotic and stemness programs.
Signaling loops are depicted with rectangular-shaped arrows. b) As a mechanism of mutual adaptation to low levels of glutamine and glucose,
CAFs provide metabolites that boost mitochondrial metabolism in cancer cells, hence fueling a resistant phenotype. Metabolites can also function
as signaling molecules, as for the lactate secreted by cancer cells that induces NF-kB-mediated transcription in CAFs, which results in secretion of
HGF that mediates TKIs resistance
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CAF-directed anti-cancer therapies, although we recom-
mend the recent review by Chen and Song for a more
extensive dissertation on this topic [5]. Several
anti-cancer strategies aiming at depleting the CAF
population have been developed so far, ranging from
metronomic chemotherapy to immune-based therapies.
The traditional maximum-tolerated dose chemotherapy
regimen has been reported to induce CAF secretion of
chemokines that endow tumor cells with CSC traits,
ultimately fostering chemoresistance. In contrast, metro-
nomic chemotherapy, which consists in administering
low doses of drug on a more frequent or continuous
schedule, prevents CAF paracrine signaling and results
in enhanced treatment response [84]. Moreover, DNA
vaccines targeting FAP have succeeded in boosting CD8+
T cell-mediated killing of CAFs in pre-clinical studies.
Remarkably, combining FAP vaccination with chemo-
therapy yielded up to 70% greater uptake of chemothera-
peutic drugs in tumor xenografts [110]. More recently,
co-administration of a novel FAP immunogen with
tumor antigen-specific DNA vaccines synergistically
enhanced antitumor immunity in mouse models of lung
and prostate cancer [111]. As an alternative
immune-based targeting strategy, adoptive transfer of
FAP-specific chimeric antigen receptor (CAR) T cells
proved to be effective in restraining tumor growth in
pre-clinical models of lung, mesothelioma and pancre-
atic cancer [112–114]. However, the feasibility of the
aforementioned approaches has been challenged by the
finding that FAP+ cells reside in almost all tissues of the
adult mouse and exert a pivotal function in preserving
tissue homeostasis in the skeletal muscle and in the
bone marrow [115].
Noteworthy, the identification of a tumor-suppressive
role of CAFs has added a further layer of complexity
[116, 117]. The recent identification of the cell surface
markers (CD10 and GPR77) specifically defining the
CAF subtype responsible for chemoresistance in breast
and lung cancer represented a breakthrough in the field
[11]. Selective targeting of such CAF subset with a
GPR77-neutralizing antibody proved to be effective in
enhancing tumor chemosensitivity in a patient-derived
xenograft (PDX) model. Alternative promising thera-
peutic options include blockade of the pathways
activated in CAFs that fuel the resistant phenotype in
tumor cells. For instance, a Smoothened inhibitor hitting
the activated Hedgehog signaling in CAFs successfully
synergized with docetaxel chemotherapy in a phase I
clinical trial enrolling TNBC patients [92]. Moreover, re-
programming activated CAFs into quiescent fibroblasts
holds great promise. Vitamin D receptor (VDR) was
identified as a druggable master regulator of the
transcriptional program orchestrating the activation of
pancreatic stellate cells [118]. Noteworthy, combined
treatment with a VDR ligand and gemcitabine in a GEM
model of pancreatic cancer resulted in dampened stro-
mal inflammation and fibrosis, improved tumor uptake
of gemcitabine and a 57% increase in survival compared
to chemotherapy alone. Blunting of CAFs’ activation has
been also achieved in bladder and pancreatic desmoplas-
tic tumors upon treatment with nanoparticles loaded
with a secretable TNF-related apoptosis-inducing ligand
(sTRAIL). Secretion of sTRAIL by CAFs upon nanopar-
ticles uptake has proved to be effective in counteracting
tumor growth by exerting a dual function. In fact, by
triggering apoptosis of adjacent tumor cells, it also
impairs activation of residual fibroblasts owing to
consequent lack of cancer cell-derived TGFβ in the
tumor milieu [119].
Conclusions
It is nowadays commonly accepted the notion that solid
tumors are complex entities where transformed cells and
stromal components coexist and influence each other in
a kind of symbiotic relationship. Hitting transformed
cells within their protective niche turns out much more
complicated than expected, due to the unraveled role of
ancillary cells. This scenario urges the need of reliable
pre-clinical models able to mimic the network of inter-
actions that are key determinant of cancer cells behavior
and response to therapy. Cancer associated fibroblasts are
one of the major components of tumor stroma and exert
mainly a supportive role in the different steps of cancer
lifespan, from the onset to the escape-dissemination phase
and ultimately to the colonization of distant organs and
resistance to therapies. Here, we have summarized the
most recent and significant findings on the role of CAFs,
with the intent to elucidate the mechanisms underlying
their crosstalk with cancer cells and the clinical outcome
of this mutual communication. CAFs are able to stimulate
pro-survival and self-renewal programs in cancer cells by
different mechanisms, mainly through the release of se-
creted paracrine factors (cytokines, exosomal vescicles,
metabolites), but also by physical remodeling of the extra-
cellular matrix, which ends up in a boosted motility of
cancer cells that are therefore more prone to metastasize.
Conversely, cancer cells actively shape CAF subpopula-
tions to hijack their metabolism in order to sustain their
survival and expansion. The close interaction between
CAFs and transformed cells can strongly influence the
clinical response to therapeutic regimens, as stromal sig-
nals foster an adaptive response of cancer cells to stress,
like drug administration or oxygen/nutrients deprivation.
In this scenario, targeting CAFs becomes an intriguing
strategy that may synergize with standard anti-tumoral ap-
proaches to target more effectively cancer. Noteworthy,
the identification of diverse subtypes of CAFs and the lack
of unique markers that identify these subpopulations
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added a further degree of complexity. Therefore, the
translation of the reported pre-clinical efforts into clinical
practice claims a better molecular characterization of
CAFs’ heterogeneity, in order to develop tailored thera-
peutic approaches able to selectively eradicate a specific
CAF subset. Moreover, despite the large body of evidence
focusing on the understanding of CAFs biology, it is im-
portant to notice that most of the studies are based on in
vitro assays, which may give rise to possible artifacts since
the culture conditions may alter the paracrine activity of
CAFs [120]. For this reason, the use of multiple cell sur-
face markers would be preferable for the isolation of CAFs
from patients’ samples, rather than selection based on
their survival advantage in culture medium. A possible
further source of artifacts and misleading results is the
limited lifespan of primary CAF cultures, before replica-
tive senescence occurs, that may strongly impair data re-
producibility. Moreover, a major challenge for the in vivo
study of CAFs is represented by the lack of an established
GEM model that allows for in vivo CAFs tracking and a
reliable imaging tool to discriminate CAFs’ dynamics dur-
ing cancer progression. Furthermore, more efforts should
be addressed to unravel the crosstalk between CAFs and
other important stromal players, such as immune cells
and endothelial cells, to finally draw a complete picture of
the TME contribution to tumor biology.
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